These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1359 related articles for article (PubMed ID: 27909164)

  • 21. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment with psilocybin: applications for patients with psychiatric disorders].
    Breeksema JJ; Koolen MHB; Somers M; Schoevers RA
    Ned Tijdschr Geneeskd; 2021 Jan; 165():. PubMed ID: 33560605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
    Muttoni S; Ardissino M; John C
    J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
    Goldberg SB; Pace BT; Nicholas CR; Raison CL; Hutson PR
    Psychiatry Res; 2020 Feb; 284():112749. PubMed ID: 31931272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
    Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
    Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial.
    Scheffold K; Philipp R; Engelmann D; Schulz-Kindermann F; Rosenberger C; Oechsle K; Härter M; Wegscheider K; Lordick F; Lo C; Hales S; Rodin G; Mehnert A
    BMC Cancer; 2015 Aug; 15():592. PubMed ID: 26286128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 33. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
    Barrett FS; Griffiths RR
    Curr Top Behav Neurosci; 2018; 36():393-430. PubMed ID: 28401522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
    Nutt D
    J Psychopharmacol; 2016 Dec; 30(12):1163-1164. PubMed ID: 27909163
    [No Abstract]   [Full Text] [Related]  

  • 35. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Psychedelics for existential distress in terminally ill patients].
    Schimmel N; Breeksema JJ; Veraart JKE; van den Brink W; Schoevers RA
    Tijdschr Psychiatr; 2020; 62(8):659-668. PubMed ID: 32816294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.